Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer
Wei Wei(Zhujiang Hospital), Jibin Li(State Key Laboratory of Pollution Control and Resource Reuse), Jundong Li(University of Virginia), Xiaohua Ban(Sun Yat-sen University), Min Zheng(Guangzhou University of Chinese Medicine), Fan Yang(Sun Yat-sen University), Rong Zhang(Columbia University Irving Medical Center), Xiao‐Feng Zhu(Sun Yat-sen University), Xin Huang(Shandong Provincial QianFoShan Hospital), Yongwen Huang(Sun Yat-sen University), Ya Qiu(Sun Yat-sen University), Qiaqia Li(Sun Yat-sen University), Xiaqin Cheng(Sun Yat-sen University)
Cited by 38
Related Papers
Feature Selection
|ACM Computing Surveys|2017|2.3k
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer
|Molecular Cancer|2019|549
Regulation of glycolytic metabolism by autophagy in liver cancer involves selective autophagic degradation of HK2 (hexokinase 2)
|Autophagy|2017|275
Line Graph Neural Networks for Link Prediction
|IEEE Transactions on Pattern Analysis and Machine Intelligence|2021|235